GridAI Technologies Corp DEFA14A, filed Jan 20, 2021
GridAI Technologies Corp. (GRDX)
DEFA14A
2021-01-20
View Original
Added on
October 17, 2026
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a)
of the Securities Exchange Act of 1934
Filed
by the Registrant [X]
Filed
by a Party other than the Registrant [ ]
Check
the appropriate box:
|
[
]
|
|
Preliminary
Proxy Statement
|
|
[
]
|
|
Confidential,
for Use of the SEC Only (as permitted by
Rule 14a-6(e)(2))
|
|
[
]
|
|
Definitive
Proxy Statement
|
|
[X]
|
|
Definitive
Additional Materials
|
|
[
]
|
|
Soliciting
Material Pursuant to 14a-12
|
AZURRX BIOPHARMA, INC.
(Name
of Registrant as Specified in Its Charter)
___________________________
(Name
of Person(s) Filing Proxy Statement, if other than the
Registrant)
Payment
of Filing Fee (Check the appropriate box):
[X]
No fee required.
[
] Fee computed on table below per
Exchange Act Rules 14a-6(i)(4) and 0-11.
|
1.
|
|
Title
of each class of securities to which transaction
applies:
|
|
2.
|
|
Aggregate
number of securities to which transaction applies:
|
|
3.
|
|
Per
unit price or other underlying value of transaction computed
pursuant to Exchange Act Rule 0-11 (set forth the amount on
which the filing fee is calculated and state how it was
determined):
|
|
4.
|
|
Proposed
maximum aggregate value of transaction:
|
|
5.
|
|
Total
fee paid:
|
[
] Fee paid previously with
preliminary materials.
[
] Check box if any part of the fee
is offset as provided by Exchange Act Rule 0-11(a)(2) and
identify the filing for which the offsetting fee was paid
previously. Identify the previous filing by registration statement
number, or the Form or Schedule and the date of its
filing.
|
1.
|
|
Amount
Previously Paid:
|
|
2.
|
|
Form,
Schedule or Registration Statement No.:
|
|
3.
|
|
Filing
Party:
|
|
4.
|
|
Date
Filed:
|
AzurRx BioPharma, Inc.
1615 South Congress Avenue, Suite 103
Delray Beach, Florida 33445
(646) 699-7855
On January 19, 2021, AzurRx BioPharma, Inc. (the
“Company”) filed a definitive proxy statement
(the “Proxy Statement”) with the Securities and
Exchange Commission in connection with a Special Meeting of
Stockholders scheduled for February 24, 2021 (the “Special
Meeting”). Due to an administrative error, the number of
shares of the Company’s common stock outstanding on January
4, 2021, the record date for the Special Meeting, was incorrectly
stated in the Proxy Statement as 34,900,382.
The correct number of shares of the Company’s
common stock outstanding as of January 4, 2021 is
31,250,382, all of which are entitled to vote at the Special
Meeting. Except as specifically supplemented by the information
contained in this supplement, all information set forth in the
Proxy Statement continues to apply and should be considered in
voting your shares.
IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY
MATERIALS
FOR THE SPECIAL MEETING TO BE HELD ON FEBRUARY 24,
2021:
This supplement, the Proxy Statement, and our official notice of
the Special Meeting of Stockholders are available at
www.proxyvote.com and on the website of the SEC at
www.sec.gov.